Aug
29
Wall Street Expats Angle for Piece of China’s Biotech Drug Boom
ByBankers, ex-pharma officials buy rights to sell drugs in China as the government loosens regulations.
A growing herd of former Wall Street bankers and drug industry veterans from the West are rushing to cash in on China’s embrace of biotechnology.
For years, China has been seen as a backwater in the pharmaceutical business. Despite its vast potential market, cumbersome regulations kept brand-name treatments from reaching patients for years after they became available elsewhere. Facing a bureaucratic gauntlet, many drugmakers either waited or didn’t bother to seek approval for blockbuster therapies in China at all…
Wall Street Expats Angle for Piece of China’s Biotech Drug Boom
